Genflow Biosciences, a UK-based biotech company focused on longevity and the development of therapies to counteract the effects of ageing, has entered into a collaborative research agreement with France-based biotechnology company, Organips.
Founded by Prof Jean Marc Lemaitre, Organips is a world leader in cellular ageing reversibility through induced pluripotent stem cells reprogramming strategies.
The collaboration will initially research the potential of the Sirtuin-6 (SIRT6) gene variant in reversing the ageing process in cells from patients with Werner Syndrome, a rare disease characterised by premature ageing.
Researchers will conduct preclinical studies on induced pluripotent stem cells to reprogramme Werner Syndrome liver organoids to make them young again as a prerequisite for future SIRT6 therapies.
The study will seek to demonstrate both the safety and efficacy of SIRT6 in reliable Werner Syndrome models.
Dr Eric Leire, Founder and CEO of Genflow, said:
“Genflow is very excited with this collaboration which gives the Company the opportunity to work with a company under the scientific advisory of Prof Jean Marc Lemaitre, who has tremendous experience in reprograming cells.
“Through this collaboration Genflow will work on reprogramming cells from patients with Werner Syndrome with the aim of taking the prematurely aged cells from Werner patients and making them young again.
“Reprograming is one of the most exciting research areas within the longevity field and is attracting significant investment, with prominent deals in the sector attracting investment capital of over $3bn last year.”
In January, Genflow became the first-ever longevity company to be listed on the London Stock Exchange.
Learn more about Genflow Biosciences and the emerging longevity industry at Age Tech World.
